Abstract
Currently, the world is battling the threat of microbial resistance to existing antimicrobial agents, resulting in overwhelming public health challenges. Response to antimicrobial agents, including antibiotics, and antiviral agents such as nucleoside or non-nucleoside analogs and the outcome of viral infections in animals and humans are proposed to have links to some host’s and viral genetics, especially mutations in viral genomes, host’s immune response, and environmental challenges such as those created by climate change. This means that these factors may influence the successful treatment of patients with antimicrobial or antiviral therapy, or disease outcomes in any infected population. This chapter reviews the origin, mechanisms, and dynamics of viral resistance, its implications for therapy, its role in disease outcomes, and innovative ways to eliminate viral resistance preventing future outbreaks.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Molecular biology of the cell, 4th edn. Garland Science, New York, NY. The structure and function of DNA. Available at: https://www.ncbi.nlm.nih.gov/books/NBK26821
Andreoni M (2003) Phenotypic resistance testing. Scand J Infect Dis Suppl 106:35–36. https://doi.org/10.1080/03008870310009632
Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci 94(13):6971–6976. https://doi.org/10.1073/pnas.94.13.6971
Bösl K, Ianevski A, Than TT, Andersen PI, Kuivanen S, Teppor M, Zusinaite E, Dumpis U, Vitkauskiene A, Cox RJ, Kallio-Kokko H, Bergqvist A, Tenson T, Merits A, Oksenych V, Bjørås M, Anthonsen MW, Shum D, Kaarbø M, Vapalahti O, Windisch MP, Superti-Furga G, Snijder B, Kainov D, Kandasamy RK (2019) Common nodes of virus-host interaction revealed through an integrated network analysis. Front Immunol 10:2186. https://doi.org/10.3389/fimmu.2019.02186. PMID: 31636628
Centre for Disease Control (CDC) (2012) Updates: influenza A (H3N2) transmission and guideline-five states. MMWR Morb Mortal Wkly Rep 60:1741–1744
Chadha J, Khullar L, Mittal N (2021) Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. Environ Microbiol 24:2615. https://doi.org/10.1111/1462-2920.15687
Chambers JP, Yu J, Valdes JJ, Arulanandam BP (2020) SARS-CoV-2, early entry events. J Pathog 2020:9238696, 11 pages. https://doi.org/10.1155/2020/9238696
Dudman SG, Stene-Johansen K, Vik IS (2008) Resistens ved virusinfeksjoner [Viral drug resistance]. Tidsskr Nor Laegeforen 128(22):2597–2600. Norwegian
Fava VM, Dallmann-Sauer M, Orlova M, Correa-Macedo W, Van Thuc N, Thai VH, Alcaïs A, Abel L, Cobat A, Schurr E (2021) Deep resequencing identifies candidate functional genes in leprosy GWAS loci. PLoS Negl Trop Dis 15(12):e0010029. https://doi.org/10.1371/journal.pntd.0010029
Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe AY, Wahl J, Bhanja S, Hwang P, Zhao Y, Robertson MN (2016) Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. J Viral Hepat 23(10):789–797. https://doi.org/10.1111/jvh.12552
Grubaugh ND, Ladner JT, Lemey P, Pybus OG, Rambaut A, Holmes EC, Andersen KG (2019) Tracking virus outbreaks in the twenty-first century. Nat Microbiol 4:10–19. https://doi.org/10.1038/s41564-018-0296-2
Gubareva LV, Webster RG, Hayden FG (2002) Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antivir Res 53(1):47–61. https://doi.org/10.1016/s0166-3542(01)00192-9
Gupta S, Kumar P, Das BC (2018) HPV: molecular pathways and targets. Curr Probl Cancer 42(2):161–174. https://doi.org/10.1016/j.currproblcancer.2018.03.003
Hahm B, Trifilo MJ, Zuniga EI, Oldstone MB (2005) Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity 22(2):247–257. https://doi.org/10.1016/j.immuni.2005.01.005
Holmes EC, Rambaut A, Andersen KG (2018) Pandemics: spend on surveillance, not prediction. Nature 558:180–182
Iannello A, Debbeche O, Martin E, Attalah LH, Samarani S, Ahmad A (2006) Viral strategies for evading antiviral cellular immune responses of the host. J Leukoc Biol 79(1):16–35. https://doi.org/10.1189/jlb.0705397
Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TFR, Hamers RL (2016) Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis 11:e267–e275
Irwin KK, Renzette N, Kowalik TF, Jensen JD (2016) Antiviral drug resistance as an adaptive process. Virus Evol 2(1):vew014. https://doi.org/10.1093/ve/vew014
Kato D, Kurebayashi Y, Takahashi T, Otsubo T, Otake H, Yamazaki M, Tamoto C, Minami A, Ikeda K, Suzuki T (2018) An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac. PLoS One 13(7):e0200761. https://doi.org/10.1371/journal.pone.0200761
Karger BL, Guttman A (2009) DNA sequencing by CE. Electrophoresis 30:S196–S202
Kurebayashi Y, Takahashi T, Otsubo T, Ikeda K, Takahashi S, Takano M, Agarikuchi T, Sato T, Matsuda Y, Minami A, Kanazawa H, Uchida Y, Saito T, Kawaoka Y, Yamada T, Kawamori F, Thomson R, von Itzstein M, Suzuki T (2014) Imaging of influenza virus sialidase activity in living cells. Sci Rep 4:4877. https://doi.org/10.1038/srep04877
L’Huillier AG, Posfay-Barbe KM (2021) Anti-infection strategies. In: Pediatric liver transplantation, pp 164–179
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X et al (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161–168
Matthew AN, Leidner F, Newton A, Ali A, KurtYilmaz N, Schiffer CA (2018) Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease. Structure 26:1360–1372. https://doi.org/10.1016/j.str.2018.07.004
Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA (2020) Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio 11(2):e00172-20. https://doi.org/10.1128/mBio.00172-20
Merigan T (1999) Viral resistance testing: practical issues and future opportunities – interview with Thomas Merigan, M.D. Interview by John S. James. AIDS Treat News (316):1–6
Morse SS (1995) Factors in the emergence of infectious diseases. Emerg Infect Dis 1(1):7–15. https://doi.org/10.3201/eid0101.950102
Nasir IA, Emeribe AU, Ojeamiren I, Aderinsayo Adekola H (2017) Human immunodeficiency virus resistance testing technologies and their applicability in resource-limited settings of Africa. Infect Dis (Auckl) 10:117863371774959. https://doi.org/10.1177/1178633717749597
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C (2017) In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 62(1):e01620–e01617. https://doi.org/10.1128/AAC.01620-17
O’Neill J (2016) Tackling drug-resistant infections globally: final report and recommendation. http://amrreview.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
Randolph HE, Fiege JK, Thielen BK, Mickelson CK, Shiratori M, Barroso-Batista J, Langlois RA, Barreiro LB (2021) Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. Science 374(6571):1127–1133. https://doi.org/10.1126/science.abg0928
Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S (2010) Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother 54(5):2085–2095. https://doi.org/10.1128/AAC.01460-09
Shafer R, Chou S (2015) Mechanisms of resistance to antiviral agents. In: Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (eds) Manual of clinical microbiology, 11th edn. ASM Press, Washington, DC, pp 1894–1912. https://doi.org/10.1128/9781555817381.ch111
Shenge JA, Odaibo GN, Olaleye DO (2018) Genetic diversity of hepatitis C virus among blood donors and patients with clinical hepatitis in Ibadan, Nigeria. Arch Basic Appl Med 6(1):79–85. PMID: 29882536
Shenge JA, Opayele AV (2020) The impact and control of emerging and re-emerging viral diseases in the environment: an African perspective. Curr Microbiol Res Africa:185–202. https://doi.org/10.1007/978-3-030-35296-7_7. PMC 7120784
Shenge JA, Odaibo GN, Olaleye DO (2021) Outbreak of measles in vaccinated population in Southeastern Nigeria. Afr J Clin Exp Microb 22(3):336–343. https://doi.org/10.4314/ajcem
Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR (2016) Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90(16):7415–7428. https://doi.org/10.1128/JVI.00080-16
Shrestha K, Acharya KP, Shrestha S (2018) One health: the interface between veterinary and human health. Int J One Health 4:8–14. https://doi.org/10.14202/IJOH
Simon-Loriere E, Holmes E (2011) Why do RNA viruses recombine? Nat Rev Microbiol 9:617–626. https://doi.org/10.1038/nrmicro2614
Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA (2016) Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J Am Chem Soc 138(36):11850–11859. https://doi.org/10.1021/jacs.6b06454
Stattermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P (2014) Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 39:1059–1070. https://doi.org/10.1371/journal.pone.0165110
Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, Dittrich S (2017) Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis 17:616. https://doi.org/10.1186/s12879-017-2713-1
Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV (2015) Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis 212(8):1209–1213. https://doi.org/10.1093/infdis/jiv245
Tavakol S, Zahmatkeshan M, Mohammadinejad R, Mehrzadi S, Joghataei MT, Alavijeh MS, Seifalian A (2021) The role of nanotechnology in current COVID-19 outbreak. Heliyon 7(4):e06841. https://doi.org/10.1016/j.heliyon.2021.e06841
Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, Meyer CG (2021) Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine 72:103629. https://doi.org/10.1016/j.ebiom.2021.103629
Virgin HW, Wherry EJ, Ahmed R (2009) Redefining chronic viral infection. Cell 138(1):30–50. https://doi.org/10.1016/j.cell.2009.06.036
Vossen MT, Westerhout EM, Söderberg-Nauclér C, Wiertz EJ (2002) Viral immune evasion: a masterpiece of evolution. Immunogenetics 54(8):527–542. https://doi.org/10.1007/s00251-002-0493-1
Wolff G, Melia CE, Snijder EJ, Bárcena M (2020) Double-membrane vesicles as platforms for viral replication. Trends Microbiol 28(12):1022–1033. https://doi.org/10.1016/j.tim.2020.05.009
WHO (2014) Antimicrobial resistance. In: Global report on surveillance. WHO, Geneva, Switzerland
World Health Organization (2020) Antimicrobial resistance. Fact sheet. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 12 Aug 2021
World Health Organization (2021) The effects of virus variants on COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines. Accessed 30 Aug 2021
Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, Malhotra-Kumar S (2016) Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium. Euro Surveill 21(27)
Zhang F, Liu L, Sun M, Sun J, Lu H (2017) An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. LoS One 12(2):e0165110
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shenge, J.A. (2023). Genetics of Viral Resistance: Clinical Relevance and Role in Viral Disease Outbreak. In: Abia, A.L.K., Essack, S.Y. (eds) Antimicrobial Research and One Health in Africa. Springer, Cham. https://doi.org/10.1007/978-3-031-23796-6_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-23796-6_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-23795-9
Online ISBN: 978-3-031-23796-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)